Female 0 6 0 6 B-gender
participants 7 19 7 19 I-gender
must 20 24 20 24 O
not 25 28 25 28 B-pregnancy
be 29 31 29 31 I-pregnancy
pregnant 32 40 32 40 I-pregnancy
, 40 41 40 41 O
breastfeeding 42 55 42 55 O
or 56 58 56 58 O
considering 59 70 59 70 O
becoming 71 79 71 79 B-pregnancy
pregnant 80 88 80 88 I-pregnancy
during 89 95 89 95 O
the 96 99 96 99 O
study 100 105 100 105 O
or 106 108 106 108 O
for 109 112 109 112 O
at 113 115 113 115 O
least 116 121 116 121 O
3 122 123 122 123 B-lower_bound
or 124 126 124 126 O
5 127 128 127 128 B-upper_bound
months 129 135 129 135 I-upper_bound
( 136 137 136 137 O
for 137 140 137 140 O
monotherapy 141 152 141 152 B-treatment
and 153 156 153 156 O
combination 157 168 157 168 B-treatment
therapy 169 176 169 176 I-treatment
participants 177 189 177 189 O
, 189 190 189 190 O
respectively 191 203 191 203 O
) 203 204 203 204 O
after 205 210 205 210 O
the 211 214 211 214 O
last 215 219 215 219 O
dose 220 224 220 224 O
of 225 227 225 227 O
study 228 233 228 233 O
drug 234 238 234 238 O

In 0 2 239 241 O
addition 3 11 242 250 O
, 11 12 250 251 O
participants 13 25 252 264 O
must 26 30 265 269 O
have 31 35 270 274 O
received 36 44 275 283 O
only 45 49 284 288 O
one 50 53 289 292 O
prior 54 59 293 298 B-treatment
immunotherapy 60 73 299 312 I-treatment

Male 0 4 313 317 B-gender
participants 5 17 318 330 I-gender
must 18 22 331 335 O
not 23 26 336 339 O
be 27 29 340 342 O
considering 30 41 343 354 O
fathering 42 51 355 364 O
a 52 53 365 366 O
child 54 59 367 372 O
or 60 62 373 375 O
donating 63 71 376 384 O
sperm 72 77 385 390 O
during 78 84 391 397 O
the 85 88 398 401 O
study 89 94 402 407 O
or 95 97 408 410 O
for 98 101 411 414 O
at 102 104 415 417 O
least 105 110 418 423 O
3 111 112 424 425 B-lower_bound
or 113 115 426 428 O
5 116 117 429 430 B-upper_bound
months 118 124 431 437 I-upper_bound
( 125 126 438 439 O
for 126 129 439 442 O
monotherapy 130 141 443 454 B-treatment
and 142 145 455 458 O
combination 146 157 459 470 B-treatment
therapy 158 165 471 478 I-treatment
participants 166 178 479 491 O
, 178 179 491 492 O
respectively 180 192 493 505 O
) 192 193 505 506 O
after 194 199 507 512 O
the 200 203 513 516 O
last 204 208 517 521 O
dose 209 213 522 526 O
of 214 216 527 529 O
study 217 222 530 535 O
drug 223 227 536 540 O

Participant 0 11 541 552 O
has 12 15 553 556 O
an 16 18 557 559 O
Eastern 19 26 560 567 B-clinical_variable
Cooperative 27 38 568 579 I-clinical_variable
Oncology 39 47 580 588 I-clinical_variable
Group 48 53 589 594 I-clinical_variable
( 54 55 595 596 I-clinical_variable
ECOG 55 59 596 600 I-clinical_variable
) 59 60 600 601 I-clinical_variable
Performance 61 72 602 613 I-clinical_variable
Status 73 79 614 620 I-clinical_variable
of 80 82 621 623 O
0 83 84 624 625 B-lower_bound
to 85 87 626 628 O
1 88 89 629 630 B-upper_bound

Participant 0 11 631 642 O
is 12 14 643 645 O
judged 15 21 646 652 O
by 22 24 653 655 O
the 25 28 656 659 O
investigator 29 41 660 672 O
to 42 44 673 675 O
have 45 49 676 680 O
evidence 50 58 681 689 O
of 59 61 690 692 O
hemolysis 62 71 693 702 B-chronic_disease

Participant 0 11 703 714 O
must 12 16 715 719 O
not 17 20 720 723 O
have 21 25 724 728 O
a 26 27 729 730 O
history 28 35 731 738 O
of 36 38 739 741 O
primary 39 46 742 749 B-chronic_disease
immunodeficiency 47 63 750 766 I-chronic_disease
, 63 64 766 767 O
bone 65 69 768 772 B-treatment
marrow 70 76 773 779 I-treatment
transplantation 77 92 780 795 I-treatment
, 92 93 795 796 O
chronic 94 101 797 804 B-cancer
lymphocytic 102 113 805 816 I-cancer
leukemia 114 122 817 825 I-cancer
, 122 123 825 826 O
solid 124 129 827 832 B-treatment
organ 130 135 833 838 I-treatment
transplantation 136 151 839 854 I-treatment
, 151 152 854 855 O
previous 153 161 856 864 O
clinical 162 170 865 873 O
diagnosis 171 180 874 883 O
of 181 183 884 886 O
tuberculosis 184 196 887 899 B-chronic_disease
, 196 197 899 900 O
inflammatory 198 210 901 913 B-chronic_disease
bowel 211 216 914 919 I-chronic_disease
disease 217 224 920 927 I-chronic_disease
, 224 225 927 928 O
interstitial 226 238 929 941 B-chronic_disease
lung 239 243 942 946 I-chronic_disease
disease 244 251 947 954 I-chronic_disease
, 251 252 954 955 O
or 253 255 956 958 O
immune 256 262 959 965 O
- 262 263 965 966 O
mediated 263 271 966 974 O
pneumonitis 272 283 975 986 B-chronic_disease

Participant 0 11 987 998 O
must 12 16 999 1003 O
not 17 20 1004 1007 O
have 21 25 1008 1012 O
a 26 27 1013 1014 O
known 28 33 1015 1020 O
uncontrolled 34 46 1021 1033 O
malignancy 47 57 1034 1044 B-cancer
of 58 60 1045 1047 I-cancer
the 61 64 1048 1051 I-cancer
central 65 72 1052 1059 I-cancer
nervous 73 80 1060 1067 I-cancer
system 81 87 1068 1074 I-cancer

Participant 0 11 1075 1086 O
must 12 16 1087 1091 O
not 17 20 1092 1095 O
have 21 25 1096 1100 O
a 26 27 1101 1102 O
prior 28 33 1103 1108 O
grade 34 39 1109 1114 O
greater 40 47 1115 1122 O
than 48 52 1123 1127 O
or 53 55 1128 1130 O
equal 56 61 1131 1136 O
to 62 64 1137 1139 O
3 65 66 1140 1141 B-lower_bound
immune 67 73 1142 1148 O
- 73 74 1148 1149 O
mediated 74 82 1149 1157 O
neurotoxicity 83 96 1158 1171 O
or 97 99 1172 1174 O
pneumonitis 100 111 1175 1186 B-chronic_disease
while 112 117 1187 1192 O
receiving 118 127 1193 1202 O
immunotherapy 128 141 1203 1216 B-treatment

Participant 0 11 1217 1228 O
must 12 16 1229 1233 O
not 17 20 1234 1237 O
have 21 25 1238 1242 O
an 26 28 1243 1245 O
active 29 35 1246 1252 O
or 36 38 1253 1255 O
prior 39 44 1256 1261 O
documented 45 55 1262 1272 O
autoimmune 56 66 1273 1283 B-chronic_disease
disease 67 74 1284 1291 I-chronic_disease
in 75 77 1292 1294 O
the 78 81 1295 1298 O
last 82 86 1299 1303 B-upper_bound
2 87 88 1304 1305 I-upper_bound
years 89 94 1306 1311 I-upper_bound

Participant 0 11 1312 1323 O
must 12 16 1324 1328 O
not 17 20 1329 1332 O
have 21 25 1333 1337 O
current 26 33 1338 1345 O
or 34 36 1346 1348 O
prior 37 42 1349 1354 O
use 43 46 1355 1358 O
of 47 49 1359 1361 O
immunosuppressive 50 67 1362 1379 B-treatment
medication 68 78 1380 1390 I-treatment
within 79 85 1391 1397 O
14 86 88 1398 1400 B-upper_bound
days 89 93 1401 1405 I-upper_bound
prior 94 99 1406 1411 I-upper_bound
to 100 102 1412 1414 O
the 103 106 1415 1418 O
first 107 112 1419 1424 O
dose 113 117 1425 1429 O
( 118 119 1430 1431 O
with 119 123 1431 1435 O
certain 124 131 1436 1443 O
exceptions 132 142 1444 1454 O
) 142 143 1454 1455 O

Participants 0 12 1456 1468 O
in 13 15 1469 1471 O
all 16 19 1472 1475 O
combination 20 31 1476 1487 B-treatment
therapy 32 39 1488 1495 I-treatment
arms 40 44 1496 1500 O
must 45 49 1501 1505 O
not 50 53 1506 1509 O
have 54 58 1510 1514 O
a 59 60 1515 1516 O
history 61 68 1517 1524 O
of 69 71 1525 1527 O
exposure 72 80 1528 1536 O
to 81 83 1537 1539 O
an 84 86 1540 1542 O
immunotherapy 87 100 1543 1556 B-treatment
experiencing 101 113 1557 1569 O
an 114 116 1570 1572 O
immune 117 123 1573 1579 O
- 123 124 1579 1580 O
mediated 124 132 1580 1588 O
adverse 133 140 1589 1596 O
event 141 146 1597 1602 O
that 147 151 1603 1607 O
required 152 160 1608 1616 O
permanent 161 170 1617 1626 O
discontinuation 171 186 1627 1642 O
of 187 189 1643 1645 O
the 190 193 1646 1649 O
immunotherapy 194 207 1650 1663 O

Participants 0 12 1664 1676 O
in 13 15 1677 1679 O
all 16 19 1680 1683 O
monotherapy 20 31 1684 1695 B-treatment
arms 32 36 1696 1700 O
must 37 41 1701 1705 O
have 42 46 1706 1710 O
an 47 49 1711 1713 O
advanced 50 58 1714 1722 O
solid 59 64 1723 1728 B-cancer
tumor 65 70 1729 1734 I-cancer
that 71 75 1735 1739 O
has 76 79 1740 1743 O
progressed 80 90 1744 1754 O
on 91 93 1755 1757 O
standard 94 102 1758 1766 B-treatment
therapies 103 112 1767 1776 I-treatment
known 113 118 1777 1782 O
to 119 121 1783 1785 O
provide 122 129 1786 1793 O
clinical 130 138 1794 1802 O
benefit 139 146 1803 1810 O
or 147 149 1811 1813 O
the 150 153 1814 1817 O
participants 154 166 1818 1830 O
are 167 170 1831 1834 O
intolerant 171 181 1835 1845 O
to 182 184 1846 1848 O
such 185 189 1849 1853 O
therapies 190 199 1854 1863 O

Participants 0 12 1864 1876 O
must 13 17 1877 1881 O
have 18 22 1882 1886 O
total 23 28 1887 1892 O
bilirubin 29 38 1893 1902 B-clinical_variable
less 39 43 1903 1907 O
than 44 48 1908 1912 O
or 49 51 1913 1915 O
equal 52 57 1916 1921 O
to 58 60 1922 1924 O
1.5 61 64 1925 1928 B-upper_bound
times 65 70 1929 1934 I-upper_bound
the 71 74 1935 1938 I-upper_bound
upper 75 80 1939 1944 I-upper_bound
limit 81 86 1945 1950 I-upper_bound
of 87 89 1951 1953 I-upper_bound
normal 90 96 1954 1960 I-upper_bound
( 97 98 1961 1962 I-upper_bound
ULN 98 101 1962 1965 I-upper_bound
) 101 102 1965 1966 I-upper_bound
, 102 103 1966 1967 I-upper_bound
and 104 107 1968 1971 O
aspartate 108 117 1972 1981 B-clinical_variable
aminotransferase 118 134 1982 1998 I-clinical_variable
and 135 138 1999 2002 O
alanine 139 146 2003 2010 B-clinical_variable
aminotransferase 147 163 2011 2027 I-clinical_variable
less 164 168 2028 2032 O
than 169 173 2033 2037 O
or 174 176 2038 2040 O
equal 177 182 2041 2046 O
to 183 185 2047 2049 O
2.5 186 189 2050 2053 B-upper_bound
times 190 195 2054 2059 I-upper_bound
ULN 196 199 2060 2063 I-upper_bound

Participants 0 12 2064 2076 O
with 13 17 2077 2081 O
a 18 19 2082 2083 O
history 20 27 2084 2091 O
of 28 30 2092 2094 O
chronic 31 38 2095 2102 B-chronic_disease
heart 39 44 2103 2108 I-chronic_disease
failure 45 52 2109 2116 I-chronic_disease
or 53 55 2117 2119 O
significant 56 67 2120 2131 O
cardiovascular 68 82 2132 2146 B-chronic_disease
disease 83 90 2147 2154 I-chronic_disease
must 91 95 2155 2159 O
have 96 100 2160 2164 O
an 101 103 2165 2167 O
echocardiogram 104 118 2168 2182 B-treatment
or 119 121 2183 2185 O
multigated 122 132 2186 2196 B-treatment
acquisition 133 144 2197 2208 I-treatment
scan 145 149 2209 2213 I-treatment
indicating 150 160 2214 2224 O
left 161 165 2225 2229 B-clinical_variable
ventricular 166 177 2230 2241 I-clinical_variable
ejection 178 186 2242 2250 I-clinical_variable
fraction 187 195 2251 2259 I-clinical_variable
greater 196 203 2260 2267 O
than 204 208 2268 2272 O
or 209 211 2273 2275 O
equal 212 217 2276 2281 O
to 218 220 2282 2284 O
45 221 223 2285 2287 B-lower_bound
% 223 224 2287 2288 I-lower_bound
within 225 231 2289 2295 O
28 232 234 2296 2298 B-upper_bound
days 235 239 2299 2303 I-upper_bound
prior 240 245 2304 2309 I-upper_bound
to 246 248 2310 2312 O
the 249 252 2313 2316 O
first 253 258 2317 2322 O
dose 259 263 2323 2327 O
of 264 266 2328 2330 O
study 267 272 2331 2336 O
drug 273 277 2337 2341 O

The 0 3 2342 2345 O
Sponsor 4 11 2346 2353 O
may 12 15 2354 2357 O
decide 16 22 2358 2364 O
to 23 25 2365 2367 O
limit 26 31 2368 2373 O
the 32 35 2374 2377 O
specific 36 44 2378 2386 O
tumor 45 50 2387 2392 B-cancer
types 51 56 2393 2398 O
selected 57 65 2399 2407 O
or 66 68 2408 2410 O
treatment 69 78 2411 2420 O
settings 79 87 2421 2429 O
for 88 91 2430 2433 O
specific 92 100 2434 2442 O
arms 101 105 2443 2447 O
based 106 111 2448 2453 O
on 112 114 2454 2456 O
evidence 115 123 2457 2465 O
gathered 124 132 2466 2474 O

articipants 0 11 2475 2486 O
in 12 14 2487 2489 O
all 15 18 2490 2493 O
combination 19 30 2494 2505 B-treatment
therapy 31 38 2506 2513 I-treatment
arms 39 43 2514 2518 I-treatment
must 44 48 2519 2523 O
have 49 53 2524 2528 O
recurrent 54 63 2529 2538 B-cancer
or 64 66 2539 2541 I-cancer
metastatic 67 77 2542 2552 I-cancer
NSCLC 78 83 2553 2558 I-cancer
and 84 87 2559 2562 O
previously 88 98 2563 2573 O
received 99 107 2574 2582 O
platinum 108 116 2583 2591 B-treatment
- 116 117 2591 2592 I-treatment
based 117 122 2592 2597 I-treatment
therapy 123 130 2598 2605 I-treatment
and 131 134 2606 2609 O
progressed 135 145 2610 2620 O
either 146 152 2621 2627 O
during 153 159 2628 2634 O
or 160 162 2635 2637 O
after 163 168 2638 2643 O
anti 169 173 2644 2648 B-treatment
- 173 174 2648 2649 I-treatment
programmed 174 184 2649 2659 I-treatment
death 185 190 2660 2665 I-treatment
ligand 191 197 2666 2672 I-treatment
1 198 199 2673 2674 I-treatment
( 200 201 2675 2676 I-treatment
PDL1)-based 201 212 2676 2687 I-treatment
therapy 213 220 2688 2695 I-treatment

